Lipsky, A. H., & Lamanna, N. (2022). Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia. Cancer, 129(1), 18–31. Portico. https://doi.org/10.1002/cncr.34510

Araujo, D., Greystoke, A., Bates, S., Bayle, A., Calvo, E., Castelo-Branco, L., de Bono, J., Drilon, A., Garralda, E., Ivy, P., Kholmanskikh, O., Melero, I., Pentheroudakis, G., Petrie, J., Plummer, R., Ponce, S., Postel-Vinay, S., Siu, L., Spreafico, A., … Seymour, L. (2023). Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Annals of Oncology, 34(1), 48–60. https://doi.org/10.1016/j.annonc.2022.09.158

Andrillon, A., Chevret, S., Lee, S. M., & Biard, L. (2022). Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐censored toxicity endpoints with competing disease progression. Statistics in Medicine, 41(29), 5753–5766. Portico. https://doi.org/10.1002/sim.9591

Chaudhary, K. R., Kinslow, C. J., Cheng, H., Silva, J. M., Yu, J., Wang, Tony. J., Hei, T. K., Halmos, B., & Cheng, S. K. (2022). Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-14448-8

Reglero, C., Dieck, C. L., Zask, A., Forouhar, F., Laurent, A. P., Lin, W.-H. W., Albero, R., Miller, H. I., Ma, C., Gastier-Foster, J. M., Loh, M. L., Tong, L., Stockwell, B. R., Palomero, T., & Ferrando, A. A. (2022). Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia. Cancer Discovery, 12(11), 2646–2665. https://doi.org/10.1158/2159-8290.cd-22-0010

Li, T., Akinade, T., Zhou, J., Wang, H., Tong, Q., He, S., Rinebold, E., Valencia Salazar, L. E., Bhansali, D., Zhong, Y., Ruan, J., Du, J., Dalerba, P., & Leong, K. W. (2022). Therapeutic Nanocarriers Inhibit Chemotherapy‐Induced Breast Cancer Metastasis. Advanced Science, 9(33). Portico. https://doi.org/10.1002/advs.202203949

Yeboah-Korang, A., Memon, A., Patel, N., Portocarrero-Castillo, A., Osman, A., Kleesattel, D., Lopez, C., Louissaint, J., Sherman, K., & Fontana, R. (2022). Impact of Prior Drug Allergies on the Risk, Clinical Features, and Outcomes of Idiosyncratic Drug-Induced Liver Injury in Adults. Digestive Diseases and Sciences, 67(11), 5262–5271. https://doi.org/10.1007/s10620-022-07403-0

Jung, S., Armstrong, E., Wei, A. Z., Ye, F., Lee, A., Carlino, M. S., Sullivan, R. J., Carvajal, R. D., Shoushtari, A. N., & Johnson, D. B. (2022). Clinical and genomic correlates of imatinib response in melanomas with KIT alterations. British Journal of Cancer, 127(9), 1726–1732. https://doi.org/10.1038/s41416-022-01942-z

Doshi, S. D., Lichtenstein, M. R. L., Beauchemin, M. P., Raghunathan, R., Lee, S., Law, C., Accordino, M. K., Elkin, E. B., Wright, J. D., & Hershman, D. L. (2022). Factors Associated With Patients Not Receiving Oral Anticancer Drugs. JAMA Network Open, 5(10), e2236380. https://doi.org/10.1001/jamanetworkopen.2022.36380

Chakraborty, R., Bhutani, D., & Lentzsch, S. (2022). How do we manage t(11;14) plasma cell disorders with venetoclax? British Journal of Haematology, 199(1), 31–39. Portico. https://doi.org/10.1111/bjh.18243

Rosenquist, R., Cuppen, E., Buettner, R., Caldas, C., Dreau, H., Elemento, O., Frederix, G., Grimmond, S., Haferlach, T., Jobanputra, V., Meggendorfer, M., Mullighan, C. G., Wordsworth, S., & Schuh, A. (2022). Clinical utility of whole-genome sequencing in precision oncology. Seminars in Cancer Biology, 84, 32–39. https://doi.org/10.1016/j.semcancer.2021.06.018

Laise, P., Bosker, G., Califano, A., & Alvarez, M. J. (2022). A Patient‐to‐Model‐to‐Patient (PMP) Cancer Drug Discovery Protocol for Identifying and Validating Therapeutic Agents Targeting Tumor Regulatory Architecture. Current Protocols, 2(9). Portico. https://doi.org/10.1002/cpz1.544

Gartrell, R. D., Blake, Z., Rizk, E. M., Perez-Lorenzo, R., Weisberg, S. P., Simoes, I., Esancy, C., Fu, Y., Davari, D. R., Barker, L., Finkel, G., Mondal, M., Minns, H. E., Wang, S. W., Fullerton, B. T., Lozano, F., Chiuzan, C., Horst, B., & Saenger, Y. M. (2022). Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma. Cancer Immunology, Immunotherapy, 71(8), 1837–1849. https://doi.org/10.1007/s00262-021-03088-y

Bansal, A., Saleh-E-In, Md. M., Kar, P., Roy, A., & Sharma, N. R. (2022). Synthesis of Carvacrol Derivatives as Potential New Anticancer Agent against Lung Cancer. Molecules, 27(14), 4597. https://doi.org/10.3390/molecules27144597

Kurz, E., Hirsch, C. A., Dalton, T., Shadaloey, S. A., Khodadadi-Jamayran, A., Miller, G., Pareek, S., Rajaei, H., Mohindroo, C., Baydogan, S., Ngo-Huang, A., Parker, N., Katz, M. H. G., Petzel, M., Vucic, E., McAllister, F., Schadler, K., Winograd, R., & Bar-Sagi, D. (2022). Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer. Cancer Cell, 40(7), 720-737.e5. https://doi.org/10.1016/j.ccell.2022.05.006

Goodwin, P. J., Chen, B. E., Gelmon, K. A., Whelan, T. J., Ennis, M., Lemieux, J., Ligibel, J. A., Hershman, D. L., Mayer, I. A., Hobday, T. J., Bliss, J. M., Rastogi, P., Rabaglio-Poretti, M., Mukherjee, S. D., Mackey, J. R., Abramson, V. G., Oja, C., Wesolowski, R., Thompson, A. M., … Parulekar, W. R. (2022). Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer. JAMA, 327(20), 1963. https://doi.org/10.1001/jama.2022.6147

Han, H., Wang, Y., Curto, J., Gurrapu, S., Laudato, S., Rumandla, A., Chakraborty, G., Wang, X., Chen, H., Jiang, Y., Kumar, D., Caggiano, E. G., Capogiri, M., Zhang, B., Ji, Y., Maity, S. N., Hu, M., Bai, S., Aparicio, A. M., … Giancotti, F. G. (2022). Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Reports, 39(1), 110595. https://doi.org/10.1016/j.celrep.2022.110595

Mazza, G. L., Petersen, M. M., Ginos, B., Langlais, B. T., Heon, N., Gounder, M. M., Mahoney, M. R., Zoroufy, A. J., Schwartz, G. K., Rogak, L. J., Thanarajasingam, G., Basch, E., & Dueck, A. C. (2021). Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2. Quality of Life Research, 31(4), 1069–1080. https://doi.org/10.1007/s11136-021-02968-1

Ma, X.-Y., Zhao, M., Li, Y.-D., Chen, Y., Wei, L., & Chen, Z.-S. (2022). Research progress in overcoming ibrutinib drug resistance. Drugs of Today, 58(2), 85–94. https://doi.org/10.1358/dot.2022.58.2.3360405

Lombardo, K. A., Obradovic, A., Singh, A. K., Liu, J. L., Joice, G., Kates, M., Bishai, W., McConkey, D., Chaux, A., Eich, M., Rezaei, M. K., Netto, G. J., Drake, C. G., Tran, P., Matoso, A., & Bivalacqua, T. J. (2021). BCG invokes superior STING‐mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer. The Journal of Pathology, 256(2), 223–234. Portico. https://doi.org/10.1002/path.5830

Yang, J., Blinzler, K., Lankin, J., Vijayakumar, S., Maculaitis, M. C., & Shelbaya, A. (2021). Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians. BioDrugs, 36(1), 71–83. https://doi.org/10.1007/s40259-021-00509-3

Chakraborty, R. (2021). Anticancer Drug Approvals in the Past Decade—Quality vs Quantity. JAMA Network Open, 4(12), e2139178. https://doi.org/10.1001/jamanetworkopen.2021.39178

Oiwa, K., Hosono, N., Nishi, R., Scotto, L., O’Connor, O. A., & Yamauchi, T. (2021). Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance. BMC Cancer, 21(1). https://doi.org/10.1186/s12885-021-08607-9

Karakasheva, T. A., Gabre, J. T., Sachdeva, U. M., Cruz-Acuña, R., Lin, E. W., DeMarshall, M., Falk, G. W., Ginsberg, G. G., Yang, Z., Kim, M. M., Diffenderfer, E. S., Pitarresi, J. R., Li, J., Muir, A. B., Hamilton, K. E., Nakagawa, H., Bass, A. J., & Rustgi, A. K. (2021). Patient-derived organoids as a platform for modeling a patient’s response to chemoradiotherapy in esophageal cancer. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-00706-8

Doussau, A., Agarwal, I., Fojo, T., Tannock, I. F., & Grady, C. (2021). Design of placebo-controlled randomized trials of anticancer agents: Ethical considerations based on a review of published trials. Clinical Trials, 18(6), 690–698. https://doi.org/10.1177/17407745211052474

Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., Joshua, A. M., Sacco, J. J., Shoushtari, A. N., Orloff, M., Piulats, J. M., Milhem, M., Salama, A. K. S., Curti, B., Demidov, L., … Piperno-Neumann, S. (2021). Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. New England Journal of Medicine, 385(13), 1196–1206. https://doi.org/10.1056/nejmoa2103485